Early-onset #colorectalcancer from patients of different races may exhibit distinct genetic features, according to a study presented at the AACR Annual Meeting 2021. Read more: https://bit.ly/3wVlAu6 #AACR21
At #AACR, we co-presented with @oncxerna on an RNA biomarker in colorectal #cancer. This is the latest achievement in our machine-learning guided approach to #biomarker development to make drug development more successful. Read more: https://www.genialis.com/2021/04/12/genialis-presents-updated-results-on-ai-enabled-rna-based-pan-cancer-biomarker-platform-at-aacr/
Today, we announced new results from our Xerna(TM) RNA-based Biomarker Platform at @AACR. The exciting results verify the capabilities of our TME Panel and enable its expanded use for patients with colorectal #cancer. Read more here: http://bit.ly/3fVNLmR
Continuing our support in developing #medicines for patients across the globe, check out this article explaining how using an #AI tool to run simulated #clinicaltrials is making it possible to include more diverse participants without any impact on safety.
#worldhealthday - Genialis aims to help develop the most promising new medicines for patients around the globe. To succeed at this we need to ensure #biomarkers account for geographic & demographic drivers & build #predictivemodels that will make #healthcare more equitable.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.